<< New tools and interventions can help in eradicating malaria | 2009 mHealth Summit discusses to integrate science and wireless solutions to improve public health >>

Schering-Plough receives FDA complete response letter regarding PEGINTRON

31. October 2009 03:09

Schering-Plough Corp. (NYSE: SGP) announced today the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

Schering-Plough will work closely with FDA to respond to outstanding concerns related to the PEGINTRON melanoma filing.

In early October, the FDA's Oncologic Drugs Advisory Committee recommended approval of PEGINTRON in this indication by a vote of 6 to 4. Schering-Plough had sought approval for this indication based on data from the largest positive adjuvant trial in subjects with stage III melanoma.

Introducing new drugs to treat malignant melanoma remains a challenge, and Schering-Plough is committed to the treatment of this aggressive form of cancer.

SOURCE Schering-Plough Corporation

c3fa1d4f-06bd-4b30-80ad-b27272ea5cd9|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Anemia, Angina, Angioedema, Anorexia, Anxiety, Arthritis, Blindness, Bone, Bone Marrow, Cancer, Cardiomyopathy, Cell, Cellulitis, Cirrhosis, Contraception, Creatinine, Depression, Dyspnea, Edema, Emphysema, Fibrosis, Gastroenteritis, Gout, Headache, Hepatitis C, Hyperglycemia, Hypersensitivity, Hyperthyroidism, Hypertriglyceridemia, Hypothyroidism, Insomnia, Lupus, Melanoma, Nausea, Neuropathy, Neutropenia, Oncology, Pancreatitis, Pneumonia, Pregnancy, Psoriasis, Psychosis, Pulmonary Hypertension, Rheumatoid Arthritis, Ribavirin, Sarcoidosis, Sepsis, Thalassemia, Thrombocytopenia, Thrombosis, Transient Ischemic Attack, Urticaria, Vasculitis, Vomiting, Weight Loss

News piece may highlight the importance of cord blood donation among Hispanic and Latino communityCORD:USE Cord Blood Bank and its program at South Miami Hospital are being featured on CNN en Espano...UK Gill Heart Institute offers individualized fitness program for heart patientsHow do you change health habits among a population with some of the highest heart disease rates in t...Organogenesis files a PMA with the FDA for its CelTx living cell-based technologyOrganogenesis, Inc. announced today that it has filed a Premarket Approval Application (PMA) with th...Acute kidney injury associated with increased long-term mortalityPatients with sudden loss of kidney function, called acute kidney injury (AKI), are more likely to d...Nitric oxide opens up new treatment option for septic shockScientists at VIB and Ghent University in Flanders, Belgium have found an unexpected ally for the tr...Alexza Pharmaceuticals submits its NDA for Staccato loxapine to FDAAlexza Pharmaceuticals, Inc. today announced that it has submitted its New Drug Application (NDA) fo...Care Support of America's outpatient palliative care coordination model improves the quality of life for seniorsCare Support of America's model of outpatient palliative care coordination, Advanced Illness Coordin...Updated clinical data from Poniard Pharmaceuticals' picoplatin Phase 2 trial announcedPoniard Pharmaceuticals, Inc. today announced updated clinical data from its randomized, controlled ...Medivir presents OPERA-1 Phase IIa trial data at the AASLD meetingData were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting...Interim data from Schering-Plough's narlaprevir Phase IIa studySchering-Plough Corporation today reported that interim results from an ongoing Phase IIa study of n...Study of combination therapy versus monotherapy for pulmonary arterial hypertensionGilead Sciences, Inc., in collaboration with GlaxoSmithKline (GSK), today announced plans for an int...Transient ischemic attacks are treatable and preventableAn estimated 200,000 Americans experience TIAs each year, and more than one-third will later have fu...New data from CIMZIA WELCOME trial to be presented at the ACG meetingAccording to new results from the WELCOME trial, exploratory data analyzing the impact of treatment ...Amarin selects Medpace as CRO for its Phase 3 AMR101 MARINE clinical studyAmarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpac...The latest medication to treat schizophrenia "ABILIFY" launched in CanadaA new treatment option for Canadians with schizophrenia, ABILIFY(TM) (aripiprazole), is now availabl...Schering-Plough receives FDA recommendation approval for PEGINTRONSchering-Plough Corp. announced today that the U.S. Food and Drug Administration's (FDA) Oncologic D...Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countriesMerck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to in...Reportlinker's report on spinal surgery marketReportlinker.com announces that a new market research report is available in its catalogue.New device for treating hypoglycemia launched globallyAt this year’s annual meeting of the International Society for Pediatric and Adolescent Diabetes (IS...Study reveals that downregulation of IRF-8 gene causes gum diseases, arthritis and osteoporosisInvestigators at Hospital for Special Surgery, collaborating with researchers from other institution...Champions Biotechnology reports higher year-on-year operating revenues for fiscal year 2009Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of ad...Three current treatment combinations for hepatitis C work equally wellThe three treatment combinations for clearing the most common form of the hepatitis C virus work equ...Study of pulmonary hypertension treatment in sickle cell patients stopped by NHLBIThe National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopp...Los Angeles Times examines increase in Caesarean births, related rise in risk, costCaesarean sections -- which are performed in 31% of births, up from 4.5% in 1965 -- often are consid...CytoDyn responds to FDA as high court rules agency cannot guarantee drug safetyCytoDyn, Inc. has sent the FDA what the Company believes is a complete response to the agency's prel...Stress may speed growth of melanoma tumorsFor patients with a particularly aggressive form of skin cancer - malignant melanoma - stress, inclu...Salmonella prompts recall of Kellogg's snacksFood and Drug Administration (FDA) officials in the United States have confirmed the presence of sal...Pegloticase BLA filing accepted for priority review by FDASavient Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has acc...Carrier screening for spinal muscular atrophy should be offered to all couplesCarrier screening for spinal muscular atrophy (SMA) - a serious genetic disease affecting approximat...GlaxoSmithKline and Cellzome announce major strategic allianceCellzome Inc. and GlaxoSmithKline have announced the signing of a worldwide strategic alliance to di...Weekends can sabotage weight-control effortsSaturday can be the worst enemy for our waistlines, according to researchers at Washington Universit...Role of breastfeeding in preventing infant death, HIV infection in developing countriesIn many poor countries, mothers with HIV face a stark choice: to nurse their infants, and risk passi...FDA approves RotarixThe U.S. Food and Drug Administration has announced the approval of Rotarix, the second oral U.S. li...New study looks at airway bypass treatment for emphysemaResearchers at Sarasota Memorial Health Care System have announced the start of the EASE (Exhale Air...Coronary heart disease: Spotting the culprit(s) is the way towards preventionA Public Lecture at Bristol University to rise awareness on a socially relevant still belittled dise...Contraceptive sponge making a comebackThe contraceptive sponge initially launched in 1983 is now making a comeback ten years down the line...Sleep disorders common among police officersSleep disorders are common, costly and treatable, but often remain undiagnosed and untreated.FDA approves new indication for FRAGMIN for the extended treatment of symptomatic venous thromboembolismThe U.S. Food and Drug Administration (FDA) has approved a new indication for FRAGMIN (dalteparin so...Generic hypertension drug a suspect in 19 deaths in PanamaAs a result of a mystery illness that has claimed the lives of 19 people, officials in Panama have w...Preconception care for improving perinatal outcomes: The time to actContinued improvements in the infant and maternal mortality rates will depend on interventions befor...Anorexia not alleviated by anti-depressantsPatients battling to deal with the eating disorder anorexia nervosa, do not benefit or prevent relap...Etanercept and chemo might reduce fatigue in cancer patientsResearchers here have found evidence that combining a drug typically used to treat rheumatoid arthri...Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseasesA retrospective case-control study of 21,008 women in Finland has found that those with intrahepatic...Link between childhood exposure to tobacco smoke and Streptococcus pneumoniaeMany of the medical risks associated with smoking, such as cancer, emphysema and heart attacks, are ...Women suffering lupus OK to take oral contraceptivesMajor study of women with either inactive or stable systemic lupus erythematosus (lupus) – a disease...University of Nottingham academic awarded prestigious professorship for research into lung diseaseAn academic at The University of Nottingham has been awarded a unique professorship by a leading nat...Discovery of mechanism in the body that could lead to autoimmune diseasesResearchers at National Jewish Medical and Research Center have discovered a mechanism in the body t...Propofol is a safe and effective drug to treat children with refractory status epilepticus...and it is recommended before thiopental, according to a study in the August 23, 2005 issue of Neu...Keep taking Viagra, it won't make you blind!In a review of its popular impotence treatment Viagra, Pfizer announced on Monday that it had found ...New treatment improves visual acuity score of patients with retinitis pigmentosaNeurotech SA announced positive results from an open-label Phase I clinical trial (03-EI-0234) of it...Mutated gene causes serious heart disease in newbornsThe research group of professor Manfred Kilimann at the Department of Cell and Molecular Biology has...Risk scores may identify young individuals with atherosclerosisYoung people with atherosclerotic lesions may be identified by a risk score calculated from coronary...Increasing benefit seen in novel drug AMN107, that treats Gleevec resistanceAn investigational drug is producing powerful responses in patients resistant to Gleevec, the target...Severe hepatitis C recurrence is more common in transplants from living donorsHepatitis C recurs with severity more often in individuals who receive liver transplants from living...Genetically engineered thyroid stimulating hormone destroys tissue that often remains after thyroidectomyA new approach to therapy can avoid most of the debilitating effects of preparing for critical, post...

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Add comment

Quirky Comment Title
Name*
E-mail* (Will show your Gravatar icon)
Country Country flag

b i u quote

Comment
Preview

Notify me when new comments are added

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

Free!

Recent Comments

Twitter

Information

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Recent Articles

Free!

Recent Comments

Twitter

Information

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Medical News Cloud

Recent Articles